2.10Open2.10Pre Close0 Volume1 Open Interest7.00Strike Price0.00Turnover868.31%IV3.92%PremiumMay 2, 2025Expiry Date1.90Intrinsic Value100Multiplier2DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type-0.5216Delta0.1051Gamma1.79Leverage Ratio-0.3114Theta-0.0004Rho-0.93Eff Leverage0.0017Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet